JP2023042506A - liquid beverage composition - Google Patents
liquid beverage composition Download PDFInfo
- Publication number
- JP2023042506A JP2023042506A JP2022022531A JP2022022531A JP2023042506A JP 2023042506 A JP2023042506 A JP 2023042506A JP 2022022531 A JP2022022531 A JP 2022022531A JP 2022022531 A JP2022022531 A JP 2022022531A JP 2023042506 A JP2023042506 A JP 2023042506A
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- water
- components
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 239000007788 liquid Substances 0.000 title claims abstract description 41
- 235000013361 beverage Nutrition 0.000 title claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 102000011931 Nucleoproteins Human genes 0.000 claims abstract description 39
- 108010061100 Nucleoproteins Proteins 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims description 81
- 238000003756 stirring Methods 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 description 59
- 239000000047 product Substances 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 19
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 16
- 239000000654 additive Substances 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000996 additive effect Effects 0.000 description 12
- 239000011734 sodium Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 159000000001 potassium salts Chemical class 0.000 description 8
- 239000012264 purified product Substances 0.000 description 8
- 159000000000 sodium salts Chemical class 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000006364 Torula Species 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 159000000007 calcium salts Chemical class 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 102000007999 Nuclear Proteins Human genes 0.000 description 4
- 108010089610 Nuclear Proteins Proteins 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241001666377 Apera Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150055528 SPAM1 gene Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- -1 mono- Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 101710149004 Nuclease P1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000975357 Salangichthys microdon Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 238000013124 brewing process Methods 0.000 description 1
- 235000012174 carbonated soft drink Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本発明は、水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩及び水分を含有する液状飲料組成物とその製造方法に関する。 The present invention relates to a liquid beverage composition containing a water-soluble nucleoprotein, a water-soluble salt of DNA, a water-soluble salt of RNA and water, and a method for producing the same.
特許文献１には、水溶性核蛋白を含有する健康ドリンクが開示されており、
特許文献２には、ＤＮＡを含有する液状食品の製造方法が開示されており、
特許文献３には、水溶性核蛋白とＲＮＡを含有する乳幼児用栄養組成物が開示されている。
Patent Document 1 discloses a health drink containing water-soluble nucleoprotein,
Patent Document 2 discloses a method for producing a liquid food containing DNA,
Patent Document 3 discloses a nutritional composition for infants containing water-soluble nucleoprotein and RNA.
水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩は、従前より人間・動物の健康に良好であることが語られてきており、栄養学的な研究も多くなされ、それぞれを人間・動物が摂取しやすいような工夫をした上で、健康食品の主成分として使用されてきた（例えば、非特許文献１及び２）。 Water-soluble nucleoproteins, water-soluble salts of DNA, and water-soluble salts of RNA have long been said to be good for the health of humans and animals. It has been used as a main component of health food after devising it so that it is easily ingested by animals (for example, Non-Patent Documents 1 and 2).
技術的知見としては、例えば、
特許文献１では、白子等に由来する核蛋白を低分子化して水溶性を向上させており、
特許文献２では、ＤＮＡに特定の溶解安定剤を添加して濁りや澱みの発生を抑制し、
特許文献３では、ＲＮＡを母乳と同様に摂取できるように設計された乳幼児用栄養組成物が検討されている。
As technical knowledge, for example,
In Patent Document 1, nucleoprotein derived from milt etc. is reduced in molecular weight to improve water solubility.
In Patent Document 2, a specific dissolution stabilizer is added to DNA to suppress the occurrence of turbidity and stagnation,
Patent Literature 3 discusses a nutritional composition for infants designed to allow RNA to be ingested in the same manner as mother's milk.
このように水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩は、それぞれは水溶性で飲料として設計できるにもかかわらず、これらを全て含有する飲料については検討されてこなかった。 Thus, the water-soluble nucleoprotein, the water-soluble salt of DNA, and the water-soluble salt of RNA are all water-soluble and can be designed as beverages, but beverages containing all of them have not been investigated.
実際、本発明に先立つ検討によって、水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩をそれぞれについて従前推奨された量比で混合した場合に、溶解性が不安定であり、不溶物が沈殿又は浮遊したり、流動性のないゲル状態になったりして、液状の飲料にすることが容易ではないことがわかった。例えば、以下のような状況である。 In fact, according to studies prior to the present invention, when the water-soluble nucleoprotein, the water-soluble salt of DNA, and the water-soluble salt of RNA are mixed in the ratios previously recommended, the solubility is unstable and the insoluble matter It has been found that it is not easy to make a liquid drink because it precipitates or floats or becomes a gel state without fluidity. For example, the situation is as follows.
市販品の水溶性核蛋白飲料である「核酸ドリンク ナチュラル DNコラーゲン」（非特許文献３：液状のDNA含有サケ白子抽出物（DNA含有率約16重量％，ｐＨ＝3.8）に、市販品の「ＤＮＡ－Ｎａ」（(有)バイオケム製、粉末）を混合しても溶解し難く不溶物が沈殿し、
市販品の水溶性核蛋白である「水溶性白子核タンパク」（(有)バイオケム製、粉末）と市販品の「ＤＮＡ－Ｎａ」（(有)バイオケム製、粉末）を水に添加するとゲル状の不溶物が浮遊又は沈殿してしまい、製造が非常に困難であり、そのままでは健康飲料として使用できない。
"Nucleic Acid Drink Natural DN Collagen" (Non-Patent Document 3: Liquid DNA-containing salmon milt extract (DNA content of about 16% by weight, pH = 3.8), which is a commercially available water-soluble nuclear protein drink, is added to the commercially available product " Even if DNA-Na" (manufactured by Biochem, powder) is mixed, it is difficult to dissolve and insoluble matter precipitates,
When water-soluble nucleoprotein "water-soluble milt nucleoprotein" (manufactured by Biochem, powder) and commercially available "DNA-Na" (manufactured by Biochem, powder) are added to water, gel-like Insoluble matter floats or precipitates, making the production very difficult and cannot be used as a health drink as it is.
また、従前の水溶性核タンパクを主成分とする飲料を含む清涼飲料は、ユーザーが求める味覚の観点と、厚生省の規制下での製造コストの観点（非特許文献４「２ 清涼飲料水の製造基準 (1) ４(ａ)（ｂ）」）とから、安定してｐＨが４未満の強い酸性飲料であることが製造サイドに要求されるため、非炭酸系清涼飲料の製造時のｐＨの範囲を４以上にすることに高いハードルがあり、非炭酸系清涼飲料の市販品のほとんどはｐＨが４．０未満である（非特許文献５）。 In addition, soft drinks containing beverages containing conventional water-soluble nuclear protein as a main ingredient are from the viewpoint of taste desired by users and the viewpoint of production costs under the regulations of the Ministry of Health and Welfare (Non-Patent Document 4 "2 Production of soft drinks Standard (1) 4(a)(b)”) requires the manufacturing side to produce strongly acidic beverages with a stable pH of less than 4. There is a high hurdle to making the range 4 or more, and most commercial non-carbonated soft drinks have a pH of less than 4.0 (Non-Patent Document 5).
特に、水溶性核タンパク、ＤＮＡ及びＲＮＡのような生体高分子系の混合飲料の場合、常温かつｐＨが４未満で異種の生体高分子の混合物が溶解し難い（ゲル状になる場合も多い）場合、混合物の製造工程で、いかなる条件の変動で不溶物が発生して製造トラブルに至るかの予測が困難であるため、かかる混合物を設計する動機付けに対するハードルはさらに高い。 In particular, in the case of mixed beverages containing biopolymers such as water-soluble nucleoproteins, DNA, and RNA, the mixture of different biopolymers is difficult to dissolve at room temperature and pH is less than 4 (it often becomes gel-like). In this case, it is difficult to predict what kind of change in conditions will cause insoluble matter to occur in the process of manufacturing the mixture, leading to manufacturing troubles.
生体高分子系清涼飲料の置かれた以上の状況の中で、水溶性核タンパク、ＤＮＡ及びＲＮＡの水溶性塩を（特に高濃度）で混合した液状飲料組成物についての技術的知見はほぼ皆無といえる。 In the above situation of biopolymer soft drinks, there is almost no technical knowledge about liquid drink compositions in which water-soluble salts of water-soluble nuclear protein, DNA and RNA are mixed (especially at high concentrations). It can be said.
本発明では、水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩を全て（又は、すべてをさらに高濃度で）含有する液状飲料組成物とその製造方法を提供することを課題とする。 An object of the present invention is to provide a liquid beverage composition containing all of water-soluble nucleoprotein, water-soluble salt of DNA and water-soluble salt of RNA (or all of them at a higher concentration) and a method for producing the same. .
本発明は、
〔１〕成分Ａ，成分Ｂ、成分Ｃ（以下「成分Ａ～Ｃ」ともいう）及び成分Ｄを含有する液状の飲料組成物であって、
前記成分Ａは水溶性核蛋白であり、
前記成分ＢはＤＮＡの水溶性塩であり、
前記成分ＣはＲＮＡの水溶性塩であり、
前記成分Ｄは水分であり、
前記成分Ａ及び前記成分Ｂの配合比は、
前記成分Ａ１００重量部に対して、前記成分Ｂが２０～３００重量部であり、
前記飲料組成物中、前記成分Ａ、Ｂ及びＣの合計配合量が２～５０重量％である液状の飲料組成物（以下「本発明１」ともいう）、並びに、
〔２〕前記成分Ａ，前記成分Ｂ及び前記成分Ｃを前記成分Ｄに溶解させる工程を含み、
前記工程が以下の工程１～４から選ばれる１以上の工程含む請求項１記載の液状の飲料組成物の製造方法：
（工程１）
前記成分Ａ１００重量部に対して、
前記成分Ｃの配合量を５０～５００重量部にして、
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を前記成分Ｄに添加して、攪拌して溶解する工程；
（工程２）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を、ｐＨの高い又は低い順に、前記成分Ｄに添加して、攪拌して溶解する工程；
（工程３）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を混合して、前記成分Ｄに添加して、前記成分Ａ～Ｄの混合液を、温度３５～９５℃で溶解する工程；
（工程４）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を混合して、前記成分Ｄに添加して、前記Ａ～Ｄの混合液を、ｐＨ４．０以上で攪拌して溶解する工程。
（以下「本発明２」ともいう）に関する（以下、本発明１及び２をまとめて「本発明」ともいう）。
The present invention
[1] A liquid beverage composition containing component A, component B, component C (hereinafter also referred to as "components A to C") and component D,
The component A is a water-soluble nucleoprotein,
The component B is a water-soluble salt of DNA,
the component C is a water-soluble salt of RNA;
The component D is water,
The blending ratio of the component A and the component B is
The component B is 20 to 300 parts by weight with respect to 100 parts by weight of the component A,
A liquid beverage composition (hereinafter also referred to as "the present invention 1") in which the total amount of the components A, B and C is 2 to 50% by weight in the beverage composition, and
[2] including a step of dissolving the component A, the component B and the component C in the component D,
The method for producing a liquid beverage composition according to claim 1, wherein the steps include one or more steps selected from the following steps 1 to 4:
(Step 1)
For 100 parts by weight of component A,
The blending amount of the component C is 50 to 500 parts by weight,
A step of adding raw materials containing the components A, B and C as main components to the component D and stirring and dissolving them;
(Step 2)
A step of adding raw materials containing the components A, B and C as main components, respectively, to the component D in order of pH from high to low, and stirring and dissolving them;
(Step 3)
A step of mixing raw materials containing the components A, B and C respectively as main components, adding the mixture to the component D, and dissolving the mixed liquid of the components A to D at a temperature of 35 to 95 ° C.;
(Step 4)
A step of mixing raw materials containing the components A, B and C as main components, adding them to the component D, and stirring and dissolving the mixture of the components A to D at a pH of 4.0 or higher.
(hereinafter also referred to as "invention 2") (hereinafter, inventions 1 and 2 are collectively referred to as "the present invention").
本発明によれば、水溶性核蛋白、ＤＮＡの水溶性塩、ＲＮＡの水溶性塩を全て（又は、全てをさらに高濃度で）含有する液状飲料組成物とその製造方法を提供することができる。 According to the present invention, it is possible to provide a liquid beverage composition containing all of water-soluble nucleoprotein, water-soluble salt of DNA and water-soluble salt of RNA (or all of them at a higher concentration) and a method for producing the same. .
〔本発明１〕
本発明１は、成分Ａ，成分Ｂ及び／又は成分Ｃ、成分Ｄ並びに成分Ｅを含有する液状の飲料組成物であって、
前記成分Ａは水溶性核蛋白であり、
前記成分ＢはＤＮＡの水溶性塩であり、
前記成分ＣはＲＮＡの水溶性塩であり、
前記成分Ｄは水分である液状の飲料組成物である。
[Invention 1]
The present invention 1 is a liquid beverage composition containing component A, component B and / or component C, component D and component E,
The component A is a water-soluble nucleoprotein,
The component B is a water-soluble salt of DNA,
the component C is a water-soluble salt of RNA;
The component D is a liquid beverage composition that is water.
（成分Ａ）
本発明１における成分Ａは水溶性核蛋白である。
(Component A)
Component A in the present invention 1 is a water-soluble nucleoprotein.
核蛋白は、生物細胞の核中に含まれ、例えば、さけ、ます、にしん、たら、いか、ほたて等の魚介類の精巣（白子とも呼ばれる）にはＤＮＡを主成分とする核酸及びプロタミンを主成分とする蛋白を多く含有する。 Nucleoproteins are contained in the nucleus of biological cells. For example, the testes (also called milt) of fish and shellfish such as salmon, trout, herring, cod, squid, and scallop contain nucleic acid and protamine, which are mainly composed of DNA. It contains a lot of protein, which is the main component.
従って、成分Ａは、例えば、白子中の核蛋白から得ることができる。 Component A can thus be obtained, for example, from nucleoproteins in milt.
核蛋白は低分子化されていると、水に０．１重量％以上の濃度で溶解し得る程度に水溶性の水溶性核蛋白となる。 When the nucleoprotein is reduced in molecular weight, it becomes a water-soluble nucleoprotein to the extent that it can be dissolved in water at a concentration of 0.1% by weight or more.
成分Ａは、好ましくは、以下の工程を経て得ることができる： Component A can preferably be obtained via the following steps:
（工程Ａ１）
白子原料を酵素処理及び／又は加水分解処理をして核蛋白複合体が分離された核蛋白混合物を得る工程。
(Step A1)
A step of enzymatically and/or hydrolyzing the milt raw material to obtain a nucleoprotein mixture from which nucleoprotein complexes have been separated.
酵素処理に使用する酵素としては、それぞれヌクレアーゼ活性及び／又はプロテアーゼ活性を有するペプシン、パンクレアチン、パパイン、ヌクレアーゼ、リパーゼ、アミラーゼ及びプロテアーゼからなる群から選ばれる少なくとも１種以上の酵素が好ましい。 At least one enzyme selected from the group consisting of pepsin, pancreatin, papain, nuclease, lipase, amylase and protease, each having nuclease activity and/or protease activity, is preferable as the enzyme used for enzymatic treatment.
成分Ａは、上記酵素処理等により低分子化される。 Component A is reduced in molecular weight by the above enzyme treatment or the like.
例えば、白子中の核蛋白をヌクレアーゼ活性を有する酵素及びプロテアーゼ活性を有する酵素で処理して得られる分子量が１０００～３０００の低分子化したオリゴヌクレオチド／ヌクレオシド及びオリゴペプチドを３０％以上含むことが、水溶性核蛋白を消化管での消化吸収を容易にする観点から好ましい。 For example, containing 30% or more of low-molecular-weight oligonucleotides/nucleosides and oligopeptides having a molecular weight of 1000 to 3000 obtained by treating nucleoprotein in milt with an enzyme having nuclease activity and an enzyme having protease activity, A water-soluble nucleoprotein is preferred from the viewpoint of facilitating digestion and absorption in the gastrointestinal tract.
（工程Ａ２）
工程Ａ１で得た核蛋白混合物を、脂質を除去するためにアルコール（好ましくは食用アルコール、より好ましくはエタノール）と接触させて抽出・精製し、必要に応じて中和、殺菌等して固液分離する工程。
(Step A2)
The nucleoprotein mixture obtained in step A1 is brought into contact with alcohol (preferably edible alcohol, more preferably ethanol) to remove lipids, extracted and purified, and if necessary neutralized, sterilized, etc. to obtain a solid-liquid solution. The process of separating.
（工程Ａ３）工程Ａ２で得た固液分離相の固形分相を回収して乾燥（好ましくは減圧乾燥又は噴霧乾燥）して水溶性核蛋白である成分Ａを含む成分Ａ含有組成物を（好ましくは粉末状で）得る工程。 (Step A3) The solid phase of the solid-liquid separated phase obtained in Step A2 is recovered and dried (preferably dried under reduced pressure or spray dried) to obtain a component A-containing composition containing component A, which is a water-soluble nucleoprotein ( (preferably in powder form).
成分Ａ含有組成物中の成分Ａの濃度は、工程Ａ１の酵素処理の程度、工程Ａ２で行われる抽出・精製の程度が進めば高くなり、成分Ａ含有組成物中のＤＮＡの重量％を目安にすることができる。 The concentration of component A in the composition containing component A increases as the degree of enzymatic treatment in step A1 and the degree of extraction/purification performed in step A2 progress, and the weight % of DNA in the composition containing component A is used as a guide. can be
成分Ａ含有組成物中の成分Ａの濃度は、成分Ａ含有組成物中のＤＮＡの重量％が４０±５重量％程度でほぼ１００重量％となり、それ以下であれば水溶性核蛋白以外の脂質等の白子原料に由来する不純物が多くなる。 The concentration of component A in the component A-containing composition is approximately 100% by weight when the weight percent of DNA in the component A-containing composition is about 40±5% by weight. There are many impurities derived from milt raw materials such as
成分Ａ含有組成物中の成分Ａの濃度は、成分Ａ含有組成物中のＤＮＡの重量％が４０±５重量％の範囲から下に外れていくほど低くなり、当該範囲から上に外れていくと水溶性核蛋白から蛋白質が剥離した核酸（ＤＮＡ）が多くなり、成分Ａ含有組成物中のＤＮＡの重量％が８５±５％程度になると、水溶性核蛋白のほぼ全量が蛋白質が剥離した核酸（ＤＮＡ）になる。 The concentration of component A in the component A-containing composition decreases as the weight percent of DNA in the component A-containing composition deviates downward from the range of 40 ± 5 wt%, and deviates upward from the range. When the weight percentage of DNA in the component A-containing composition reaches about 85±5%, almost all of the water-soluble nucleoprotein is detached. It becomes nucleic acid (DNA).
そこで、本発明では、白子から抽出・精製した成分Ａ含有組成物中の成分Ａの濃度ＸＡは以下の要領で計算する。 Therefore, in the present invention, the concentration XA of component A in the composition containing component A extracted and purified from milt is calculated in the following manner.
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが４０重量％以下の場合〕
ＸＡ＝１００×ＸＤＮＡ／４０（重量％） （Ａ－１）
[When the DNA concentration X DNA in the component A-containing composition is 40% by weight or less]
X A =100×X DNA /40 (% by weight) (A-1)
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが４０重量％超８５重量％の場合〕
ＸＡ＝１００×（１－（ＸＤＮＡ－４０）／４５）（重量％） （Ａ－２）
[When the DNA concentration X DNA in the component A-containing composition is more than 40% by weight and 85% by weight]
XA = 100 x (1-(X DNA -40)/45) (% by weight) (A-2)
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが８５重量％超の場合〕
成分Ａ含有組成物中の成分Ａの濃度ＸＡは０重量％とする。
[When the DNA concentration X DNA in the component A-containing composition exceeds 85% by weight]
The concentration XA of component A in the composition containing component A is 0% by weight.
上記工程Ａ１～Ａ３で得た成分Ａ含有組成物中のＤＮＡの重量％は、好ましくは３０～７０重量％、より好ましくは４０～６５重量％、更に好ましくは５０～６０重量％、
さらに、成分Ａの有効利用の観点から、好ましくは３０～６０重量％、更に好ましくは３０～５０重量％、更に好ましくは３５～６５重量％、更に好ましくは３５～４５重量％、更に好ましくは３８～４２重量％である。
The weight % of DNA in the component A-containing composition obtained in steps A1 to A3 is preferably 30 to 70% by weight, more preferably 40 to 65% by weight, still more preferably 50 to 60% by weight,
Furthermore, from the viewpoint of effective utilization of component A, preferably 30 to 60% by weight, more preferably 30 to 50% by weight, still more preferably 35 to 65% by weight, still more preferably 35 to 45% by weight, still more preferably 38% by weight ~42% by weight.
なお、上述の成分Ａ含有組成物中のＤＮＡの重量％は、例えば、紫外可視吸光光度検出ＨＰＬＣを使用して、ＤＮＡの吸収ピーク波長である２６０ｎｍでの吸光度に基づいて算出することができる。
具体的には、例えば、上記工程Ａ１における白子原料Ｘと、上記工程Ａ３における成分Ａ含有組成物Ｙについて、以下の手順を行う。
The weight % of DNA in the component A-containing composition described above can be calculated based on the absorbance at 260 nm, which is the absorption peak wavelength of DNA, using, for example, UV-visible absorption detection HPLC.
Specifically, for example, the following procedure is performed for the soft roe raw material X in the above step A1 and the component A-containing composition Y in the above step A3.
（１）前処理：白子原料Ｘと成分Ａ含有組成物Ｙのそれぞれ3mlに、0.1mol/Lリン酸緩衝液(pH=5.3)4ml、0.01mol/L塩化亜鉛溶液1ml、0.010.01mol/LヌクレアーゼP1溶液2mlを加え、60℃2時間の加温処理をして白子原料Ｘの前処理液Ｘ及び成分Ａ含有組成物Ｙの前処理液Ｙを得る。 (1) Pretreatment: To each 3 ml of milt raw material X and component A-containing composition Y, 4 ml of 0.1 mol/L phosphate buffer (pH=5.3), 1 ml of 0.01 mol/L zinc chloride solution, 0.010.01 mol/L Add 2 ml of the nuclease P1 solution and heat at 60° C. for 2 hours to obtain a pretreatment liquid X for the milt raw material X and a pretreatment liquid Y for the component A-containing composition Y.
（２）前処理液Ｘ及び前処理液について、ＨＰＬＣ測定条件：例えば、三菱化学社製イオン交換樹脂カラム（MCI GEL CDR-10）を使用した紫外可視吸光光度検出島津製作所製ＨＰＬＣ測定システムを用いて、標準的なＨＰＬＣの測定条件（例えば、
前処理液Ｘではカラム温度40℃、移動相が酢酸緩衝液（pH＝3.3）1mol/L、流量1.0ｍl/min、
前処理液Ｙではカラム温度60℃、移動相が酢酸緩衝液（pH＝3.3）1.4mol/L、流量1.0ｍl/min）で、前処理液Ｘ及び前処理液Ｙの吸光度に基づいて、
白子原料Ｘ中の成分Ａの濃度ＣＸ、及び、含有組成物Ｙ中の成分Ａの濃度ＣＹを算出し、
ΔＣＡ＝ＣＹ－ＣＸをＤＮＡの濃度とした。
なお、ΔＣＡは、紫外可視吸光光度検出ＨＰＬＣで検出できるＤＮＡ由来のデオキシリボヌクレオチドの濃度の総和である。
(2) HPLC measurement conditions for pretreatment liquid X and pretreatment liquid: For example, an HPLC measurement system manufactured by Shimadzu Corporation using an ion-exchange resin column (MCI GEL CDR-10) manufactured by Mitsubishi Chemical Corporation and an ultraviolet-visible absorption photometric detection system manufactured by Shimadzu Corporation. and standard HPLC measurement conditions (for example,
For pretreatment solution X, the column temperature was 40°C, the mobile phase was acetate buffer (pH = 3.3) 1 mol/L, the flow rate was 1.0 mL/min,
For pretreatment liquid Y, the column temperature is 60°C, the mobile phase is acetate buffer (pH = 3.3) 1.4 mol/L, the flow rate is 1.0 ml/min).
Calculate the concentration C X of the component A in the milt raw material X and the concentration CY of the component A in the containing composition Y,
ΔC A =C Y -C X was taken as the concentration of DNA.
ΔC A is the total concentration of DNA-derived deoxyribonucleotides that can be detected by UV-visible absorptiometric detection HPLC.
成分Ａは、例えば白子を酵素処理して核蛋白を低分子化したものを、分画せずにそのまま又は吸着剤等を添加して不純物を沈殿させ上澄みを採取する程度の精製して使用してもよく、分画物を採取して低分子化した水溶性核蛋白の純度を向上したものでもよい。 Component A is used, for example, by enzymatically treating milt to reduce the molecular weight of the nucleoprotein, without fractionation, or after purification to the extent that impurities are precipitated by adding an adsorbent or the like and the supernatant is collected. Alternatively, it may be a water-soluble nucleoprotein obtained by collecting a fraction and reducing the molecular weight thereof to improve its purity.
（成分Ｂ）
成分Ｂは、例えば、しらこに含まれる核蛋白に、蛋白質分解酵素（例えば、プロテアーゼ）を作用させて、核蛋白中のＤＮＡの濃度を向上し、さらに、脂質を除去するためにアルコール（好ましくは食用アルコール、より好ましくはエタノール）と接触させて抽出・精製し、遠心分離等を組合わせて得た精製物を利用することができ、さらに精製物を分画処理して所望の範囲の分子量のＤＮＡを多く含む精製物を利用することができる。
(Component B)
Component B, for example, acts on the nucleoprotein contained in whitebait with a proteolytic enzyme (e.g., protease) to improve the concentration of DNA in the nucleoprotein, and alcohol (preferably is an edible alcohol, more preferably ethanol), extracted and purified, and the purified product obtained by a combination of centrifugation and the like can be used, and the purified product is further fractionated to a desired range of molecular weight A DNA-enriched purified product of is available.
成分Ｂは、
白子原料をヌクレアーゼ活性を有する酵素で処理しない高分子量型ＤＮＡ（以下「成分Ｂ１」ともいう）と、
白子原料をヌクレアーゼ活性を有する酵素で処理してＤＮＡの分子量を低減させた低分子量型ＤＮＡ（以下「成分Ｂ２」ともいう）とを好ましく使用することができる。
Component B is
high-molecular-weight DNA (hereinafter also referred to as “component B1”) in which the milt raw material is not treated with an enzyme having nuclease activity;
A low-molecular-weight DNA (hereinafter also referred to as “component B2”) obtained by treating a milt raw material with an enzyme having nuclease activity to reduce the molecular weight of the DNA can be preferably used.
成分ＢのＤＮＡ水溶性塩を形成する塩基としては、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩、リチウム塩、アルミニウム塩などの無機塩；メチルアミン塩、ジメチルアミン塩、トリエチルアミン塩のようなモノ－、ジ－及びトリ－アルキルアミン塩、モノ－、ジ－及びトリ－ヒドロキシアルキルアミン塩、グアニジン塩、Ｎ－メチルグルコサミン塩などの有機塩を挙げることができ、水溶性の観点から、無機塩であることが好ましく、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩及びリチウム塩からなる群から選ばれる１種以上の塩であることがより好ましく、ナトリウム塩、カリウム塩及びカルシウム塩からなる群から選ばれる１種以上の塩であることが更に好ましく、ナトリウム塩及び／又はカリウム塩であることが更に好ましい。 Examples of bases that form DNA water-soluble salts of component B include inorganic salts such as sodium salts, potassium salts, calcium salts, magnesium salts, ammonium salts, lithium salts and aluminum salts; Organic salts such as mono-, di- and tri-alkylamine salts, mono-, di- and tri-hydroxyalkylamine salts, guanidine salts, N-methylglucosamine salts can be mentioned, and from the viewpoint of water solubility , preferably inorganic salts, more preferably one or more salts selected from the group consisting of sodium salts, potassium salts, calcium salts, magnesium salts, ammonium salts and lithium salts, sodium salts, potassium salts and It is more preferably one or more salts selected from the group consisting of calcium salts, more preferably sodium salts and/or potassium salts.
本発明においては、成分Ｂは、成分Ｂ１又は成分Ｂ２であってよいが、体内吸収性の観点から、成分Ｂ１と成分Ｂ２の混合物であることが好ましい。 In the present invention, component B may be component B1 or component B2, but is preferably a mixture of component B1 and component B2 from the viewpoint of absorption into the body.
成分Ａ含有組成物のＤＮＡ重量％を増大させた場合、成分Ａ含有組成物中の成分Ｂの濃度ＸＢを以下の要領で計算する。 As the DNA weight percent of the component A containing composition is increased, the concentration XB of component B in the component A containing composition is calculated as follows.
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが４０重量％以下の場合〕
成分Ａ含有組成物中の成分Ｂの濃度ＸＢは０重量％とする。
[When the DNA concentration X DNA in the component A-containing composition is 40% by weight or less]
The concentration XB of component B in the composition containing component A is 0% by weight.
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが４０重量％超８５重量％の場合〕
ＸＢ＝ＸＤＮＡ×（１－ＸＡ／１００）（重量％） （Ｂ－１）
[When the DNA concentration X DNA in the component A-containing composition is more than 40% by weight and 85% by weight]
X B = X DNA × (1-X A /100) (% by weight) (B-1)
〔成分Ａ含有組成物中のＤＮＡ濃度ＸＤＮＡが８５重量％超の場合〕
成分Ａ含有組成物中の成分Ｂの濃度ＸＢはＸＤＮＡ重量％とする。
[When the DNA concentration X DNA in the component A-containing composition exceeds 85% by weight]
The concentration X B of component B in the composition containing component A is X DNA weight percent.
上記の工程で得た成分Ｂ１を含む精製物（原料組成物）中の成分Ｂ１の濃度（重量％）は、好ましくは７０～９９重量％、より好ましくは７５～９５重量％、更に好ましくは８０～９０重量％、更に好ましくは８３～８７重量％である。 The concentration (% by weight) of component B1 in the purified product (raw material composition) containing component B1 obtained in the above steps is preferably 70 to 99% by weight, more preferably 75 to 95% by weight, and still more preferably 80% by weight. ~90% by weight, more preferably 83-87% by weight.
上記工程で得た成分Ｂ２を含む精製物（原料組成物）中の成分Ｂ２の濃度（重量％）は、好ましくは７０～９９重量％、より好ましくは８０～９７重量％、更に好ましくは８５～９５重量％、更に好ましくは８８～９２重量％である。 The concentration (% by weight) of component B2 in the purified product (raw material composition) containing component B2 obtained in the above step is preferably 70 to 99% by weight, more preferably 80 to 97% by weight, still more preferably 85 to 95% by weight, more preferably 88 to 92% by weight.
なお、成分Ｂ１及びＢ２の濃度（重量％）は、ＤＮＡ中のリン酸基に着目し、成分Ｂ１又はＢ２を含む精製物中のリン酸濃度を、フランス薬局方のバナドモリブデン酸吸光光度法（吸光波長４００ｎｍ）に基づき測定して、ＤＮＡ濃度に換算した。 The concentration (% by weight) of components B1 and B2 is determined by focusing on the phosphate group in DNA, and the concentration of phosphate in the purified product containing component B1 or B2 is determined by the vanadomolybdate spectrophotometry method of the French Pharmacopoeia. (absorbance wavelength 400 nm) and converted to DNA concentration.
（成分Ｃ）
成分ＣはＲＮＡの水溶性塩である。
(Component C)
Component C is a water-soluble salt of RNA.
食品用とで使用されるＲＮＡは、ビール酵母、パン酵母が食品用として知られるSaccharoyces属酵母由来の酵母エキス、トルラ酵母として知られるTorula属酵母由来の酵母エキスに含まれる酵母の菌体内に多く含まれ、これらの酵母エキス（好ましくはトルラ酵母由来の酵母エキス）から抽出・精製して得ることができる。 RNA used for food is contained in yeast cells contained in brewer's yeast, yeast extract derived from Saccharoyces genus yeast known as baker's yeast for food, and yeast extract derived from Torula genus yeast known as torula yeast. It can be obtained by extracting and purifying from these yeast extracts (preferably yeast extract derived from torula yeast).
ＲＮＡは、酵母、細菌、乳、魚介類、動物、及び／又は植物など生物の抽出由来のものが好ましく、食品用として従前より開発されている酵母の抽出由来のものがより好ましい。 RNA is preferably extracted from organisms such as yeast, bacteria, milk, seafood, animals, and/or plants, and more preferably extracted from yeast that has been developed for food.
酵母の抽出由来のＲＮＡは、ビール酵母、パン酵母が食品用として知られるSaccharoyces属酵母由来の酵母エキス、トルラ酵母として知られるTorula属酵母由来の酵母エキスに含まれる酵母の菌体内に多く含まれ、これらの酵母エキス（好ましくはトルラ酵母由来の酵母エキス）から抽出・精製して得ることができる。 Yeast extract-derived RNA is abundantly contained in yeast cells contained in brewer's yeast, baker's yeast, yeast extract derived from Saccharoyces genus yeast known for food use, and yeast extract derived from Torula genus yeast known as torula yeast. , can be obtained by extracting and purifying from these yeast extracts (preferably yeast extract derived from torula yeast).
生酵母でも、熱処理、化学的処理、生化学的処理、物理的処理等を行った酵母であっても、更には酒類等の醸造工程から回収される余剰酵母なども利用することができる。 Raw yeast, yeast that has been subjected to heat treatment, chemical treatment, biochemical treatment, physical treatment, etc., and surplus yeast collected from the brewing process of alcoholic beverages can also be used.
成分Ｃは、好ましくは、以下の工程を経て得ることができる： Component C can preferably be obtained via the following steps:
トルラ酵母（Ｎａ塩）を水系溶媒（例えば、水）に溶解させて、必要に応じて殺菌して濾過して乾燥（好ましくは減圧乾燥又は噴霧乾燥）してＲＮＡ水溶性塩である成分Ｃを含有する組成物（以下「簡易精製組成物」ともいう）を得ることができる（以下、「簡易精製組成物」中の成分Ｃを「成分Ｃ１」ともいう）。 Torula yeast (Na salt) is dissolved in an aqueous solvent (e.g. water), sterilized if necessary, filtered and dried (preferably vacuum drying or spray drying) to obtain component C, which is an RNA water-soluble salt. It is possible to obtain a composition (hereinafter also referred to as "simplified purification composition") containing it (hereinafter, component C in the "simplified purification composition" is also referred to as "component C1").
成分Ｃは、さらに脂質を除去するためにアルコール（好ましくは食用アルコール、より好ましくはエタノール）と接触させて抽出・精製を繰り返して、必要に応じて、不純物の吸着、殺菌を行い、高純度化することができる（以下、「高精製組成物」中の成分Ｃを「成分Ｃ２」ともいう）。 Component C is further subjected to contact with alcohol (preferably edible alcohol, more preferably ethanol) in order to remove lipids, repeated extraction and purification, and if necessary, adsorption of impurities, sterilization, and high purification. (hereinafter, component C in the "highly purified composition" is also referred to as "component C2").
成分ＣのＲＮＡ水溶性塩を形成する塩基としては、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩、リチウム塩、アルミニウム塩などの無機塩；メチルアミン塩、ジメチルアミン塩、トリエチルアミン塩のようなモノ－、ジ－及びトリ－アルキルアミン塩、モノ－、ジ－及びトリ－ヒドロキシアルキルアミン塩、グアニジン塩、Ｎ－メチルグルコサミン塩などの有機塩を挙げることができ、水溶性の観点から、無機塩であることが好ましく、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩及びリチウム塩からなる群から選ばれる１種以上の塩であることがより好ましく、ナトリウム塩、カリウム塩及びカルシウム塩からなる群から選ばれる１種以上の塩であることが更に好ましく、ナトリウム塩及び／又はカリウム塩であることが更に好ましい。 Bases that form RNA water-soluble salts of component C include inorganic salts such as sodium salts, potassium salts, calcium salts, magnesium salts, ammonium salts, lithium salts and aluminum salts; methylamine salts, dimethylamine salts and triethylamine salts; Organic salts such as mono-, di- and tri-alkylamine salts, mono-, di- and tri-hydroxyalkylamine salts, guanidine salts, N-methylglucosamine salts can be mentioned, and from the viewpoint of water solubility , preferably inorganic salts, more preferably one or more salts selected from the group consisting of sodium salts, potassium salts, calcium salts, magnesium salts, ammonium salts and lithium salts, sodium salts, potassium salts and It is more preferably one or more salts selected from the group consisting of calcium salts, more preferably sodium salts and/or potassium salts.
上記工程で得た精製物(原料組成物)の成分Ｃ１又はＣ２の濃度（重量％）は、好ましくは７０～９９重量％、より好ましくは７５～９５重量％、更に好ましくは８０～９０重量％である。 The concentration (% by weight) of component C1 or C2 in the purified product (raw material composition) obtained in the above step is preferably 70 to 99% by weight, more preferably 75 to 95% by weight, and still more preferably 80 to 90% by weight. is.
なお、成分Ｃ１及びＣ２の濃度（重量％）は、ＤＮＡ中のリン酸基に着目し、成分Ｂ１又はＢ２を含む精製物中のリン酸濃度を、医薬部外品原料規格2021「デオキシリボ核酸ナトリウム 定量法（２）リン」に準拠してリン濃度を求め、ＤＮＡ濃度に換算した。 In addition, the concentration (% by weight) of components C1 and C2 focuses on the phosphate group in DNA, and the phosphate concentration in the purified product containing component B1 or B2 is determined by the quasi-drug raw material standard 2021 "Deoxyribonucleic acid sodium Phosphorus concentration was determined according to Quantitative method (2) Phosphorus and converted to DNA concentration.
（成分Ａ～Ｃの形態と市販品の例）
成分Ａ～Ｃを主成分として含む原料（以下、まとめて「成分Ａ～Ｃ原料」、それぞれ「成分Ａ原料」「成分Ｂ原料」「成分Ｃ原料」という）は、水溶液、懸濁液、ゼリー状又は乾燥粉末等の形態であってよいが、他の成分との混合性及び本発明１の生産性の観点から、水溶液又は乾燥粉末であることが好ましく、乾燥粉末であることがより好ましい。
(Forms of components A to C and examples of commercially available products)
Raw materials containing components A to C as main components (hereinafter collectively referred to as “component A to C raw materials”, respectively “component A raw materials”, “component B raw materials” and “component C raw materials”) are aqueous solutions, suspensions, jelly Although it may be in the form of a liquid or a dry powder, it is preferably an aqueous solution or a dry powder, and more preferably a dry powder, from the viewpoint of mixability with other components and productivity of the present invention 1.
成分Ａを主成分とする市販品としては例えば『水溶性白子核タンパク』（(有)バイオケム製）；
成分Ｂ１を主成分とする市販品としては例えば『ＤＮＡ-Ｎａ』（(有)バイオケム製）；
成分Ｂ２を主成分とする市販品としては例えば『ＤＮＡ-Ｎａ（Ｆ）』（(有)バイオケム製）；
成分Ｃ１を主成分とする市販品としては、例えば『ＲＮＡ』（(有)バイオケム製）；
成分Ｃ２を主成分とする市販品としては、例えば『ＲＮＡ（Ｗ）』（(有)バイオケム製）を挙げることができる（いずれも粉末である）。
Commercially available products containing component A as a main component include, for example, "water-soluble milt nucleus protein" (manufactured by Biochem Co., Ltd.);
Examples of commercially available products containing component B1 as a main component include "DNA-Na" (manufactured by Biochem Co., Ltd.);
Examples of commercially available products containing component B2 as a main component include "DNA-Na (F)" (manufactured by Biochem);
Commercially available products containing component C1 as a main component include, for example, "RNA" (manufactured by Biochem Co., Ltd.);
Commercially available products containing component C2 as a main component include, for example, "RNA (W)" (manufactured by Biochem Co., Ltd.) (both of which are powders).
（１）成分Ａ原料：製品名『水溶性白子核タンパク』（成分Ａは４０重量％）
（２）成分Ｂ１原料：製品名『ＤＮＡ-Ｎａ』（成分Ｂ１は８５重量％）
（３）成分Ｂ２原料：製品名『ＤＮＡ-Ｎａ（Ｆ）』（成分Ｂ２は９０重量％）
（４）成分Ｃ１原料：製品名『ＲＮＡ』（成分Ｃ１は８５重量％）
（５）成分Ｃ２原料：製品名『ＲＮＡ－Ｗ』（成分Ｃ２は８５重量％）
(1) Component A raw material: product name "water-soluble milt nucleus protein" (40% by weight of component A)
(2) Component B1 raw material: product name "DNA-Na" (85% by weight of component B1)
(3) Component B2 raw material: product name "DNA-Na (F)" (component B2 is 90% by weight)
(4) Component C1 raw material: product name “RNA” (component C1 is 85% by weight)
(5) Component C2 raw material: product name “RNA-W” (component C2 is 85% by weight)
（成分Ｄ）
成分Ｄは水分である。
(Component D)
Component D is water.
成分Ｄは、成分Ａ～Ｃをと主成分とする原料と成分Ａ～Ｃ以外の成分を主成分とする原料に含まれる水分と、これらの原料とは別に添加した水分の合計である。 Component D is the sum of water contained in raw materials containing components A to C as main components and raw materials containing components other than components A to C as main components, and water added separately from these raw materials.
水分としては、「清涼飲料水の製造基準」において定義される「飲用適の水」が使用でき、例えば、飲用適の水として使用できる天然湧水、日本で使用される硬度（好ましくは１０～３００、より好ましくは２０～２００、更に好ましくは３０～１００、更に好ましくは４０～９０）の水道水、当該水道水を原料とする精製水（蒸留水、イオン交換水、脱イオン水等）を使用できるが、成分Ａ～Ｃの溶解性と味覚の観点から精製水であることが好ましい。 As water, "drinkable water" defined in "soft drink manufacturing standards" can be used. For example, natural spring water that can be used as drinkable water, hardness used in Japan (preferably 300, more preferably 20 to 200, more preferably 30 to 100, still more preferably 40 to 90) tap water, purified water (distilled water, ion-exchanged water, deionized water, etc.) made from the tap water Although it can be used, purified water is preferred from the viewpoint of the solubility of components A to C and taste.
（任意成分）
本発明１は、成分Ａ～Ｄの他に、本発明１における成分Ａ～Ｄの効果を阻害しない範囲で、飲料用の成分を配合することができ、例えば、亜鉛、コラーゲン；コンドロイチン；ヒアルロン酸；ビタミンＣ、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２等のビタミン類又はアスコルビン酸ジグリコシド等のビタミン類誘導体；クエン酸、クエン酸ナトリウム、乳酸、乳酸ナトリウム、ＤＬ-リンゴ酸等のｐＨ調整剤；ミネラル類；アミノ酸類；ペプチド類；糖類；水溶性食物繊維；果物又は野菜の汁；蜂蜜；酸味料；甘味料；香料；保存料；着色料及びナノコロイドシリカ等の無機微粒子等を配合することができる。
(Optional component)
In the present invention 1, in addition to the components A to D, ingredients for beverages can be blended within the range that does not inhibit the effects of the components A to D in the present invention 1. For example, zinc, collagen; chondroitin; hyaluronic acid vitamins such as vitamin C, vitamin B1, vitamin B2, vitamin B6 and vitamin B12 or vitamin derivatives such as ascorbic acid diglycoside; pH adjusters such as citric acid, sodium citrate, lactic acid, sodium lactate, and DL-malic acid Minerals; Amino acids; Peptides; Sugars; Water-soluble dietary fiber; Fruit or vegetable juice; Honey; be able to.
（液状の飲料組成物）
成分Ａ～Ｃを所定の組成で配合することによって、成分Ａ～Ｄを含有する液状の飲料組成物である本発明１を得ることができる。
(Liquid beverage composition)
By blending components A to C in a predetermined composition, the present invention 1, which is a liquid beverage composition containing components A to D, can be obtained.
ＤＮＡの水溶性塩である成分Ｂは、人体の細胞の新陳代謝の促進、免疫力の向上、抗疲労、持久力向上に寄与すると考えられている（非特許文献１及び２）。 Component B, which is a water-soluble salt of DNA, is believed to contribute to acceleration of human cell metabolism, improvement of immunity, anti-fatigue, and improvement of endurance (Non-Patent Documents 1 and 2).
成分Ｂのうち、原料（例えば白子核蛋白）中の核蛋白内のＤＮＡの分子量のまま抽出された成分Ｂ１は、相対的に体内への消化吸収が相対的にし難く、
成分Ｂのうち、原料（例えば白子核蛋白）中の核蛋白内のＤＮＡの分子量を酵素反応等により低減して抽出された成分Ｂ２は、相対的に体内への消化吸収が相対的にし易いので、時間をかけて消化する必要がある場合は成分Ｂ１が好ましく
胃や腸などの消化器官が弱っている場合には成分Ｂ２が好ましい。
Of component B, component B1, which is extracted with the molecular weight of the DNA in the nucleoprotein in the raw material (e.g., milt nucleoprotein), is relatively difficult to digest and absorb into the body.
Of component B, component B2, which is extracted by reducing the molecular weight of the DNA in the nucleoprotein in the raw material (e.g., milt nucleoprotein) by enzymatic reaction or the like, is relatively easily digested and absorbed into the body. Ingredient B1 is preferred when it is necessary to take a long time to digest, and ingredient B2 is preferred when digestive organs such as the stomach and intestines are weakened.
成分Ｂ１及び成分Ｂ２が配合されていると、混合物の体内での消化が、まず成分２が消化され、次第に成分Ｂ１が消化されていくので、成分１及び２の配合比を変えることで成分Ｂの消化時間を制御することができる。 When component B1 and component B2 are blended, the digestion of the mixture in the body is such that component 2 is digested first and then component B1 is gradually digested. of digestion time can be controlled.
水溶性核蛋白である成分Ａは、精巣から抽出される核蛋白を原料とし、ＤＮＡに加えて、プロタミン等の蛋白質を含み、ＤＮＡによる効能に加えて、抗酸化化の向上、血糖値の安定化、血流促進、筋肉増強、成長ホルモンの分泌等に寄与すると考えられている（非特許文献１及び２）。 Component A, which is a water-soluble nucleoprotein, is made from the nucleoprotein extracted from the testis, and contains proteins such as protamine in addition to DNA. It is believed to contribute to mobilization, blood flow promotion, muscle strengthening, growth hormone secretion, etc. (Non-Patent Documents 1 and 2).
ＲＮＡの水溶性塩である成分Ｃは、認知症の予防・改善にも繋がる、脳の神経細胞の活性維持、免疫機能の維持等に寄与すると考えられている（非特許文献１及び２）。 Component C, which is a water-soluble salt of RNA, is believed to contribute to the maintenance of neuronal activity in the brain, the maintenance of immune function, etc., which leads to the prevention and improvement of dementia (Non-Patent Documents 1 and 2).
本発明１に成分Ａ～Ｃが配合されることで、上述各成分の効能を備えるだけでなく、成分Ａ～Ｃの配合比を制御し、さらに、成分Ａ～Ｃ中のＤＮＡ、ＲＮＡ及び蛋白質の効能をより効率的に促進すると言われるビビタミンＢ類、ビタミンＣ類、細胞間の正常なタンパク質の品質管理に働くと考えられる亜鉛酵母等を組み合わせて消化吸収のしやすい飲料組成物を得ることができる。 By blending the components A to C in the present invention 1, it not only provides the efficacy of each component described above, but also controls the blending ratio of the components A to C, and furthermore, DNA, RNA and protein in the components A to C. To obtain an easily digestible and absorbable beverage composition by combining bivitamins B and vitamin C, which are said to more efficiently promote the efficacy of , and zinc yeast, etc., which are thought to work for normal protein quality control between cells. can be done.
本発明１における成分Ｂの体内吸収性の観点から、
成分Ａ及びＢの配合比は、成分Ａ１００重量部に対して、
成分Ｂが、好ましくは３０～５００重量部、より好ましくは５０～４００重量部、更に好ましくは６０～３００重量部、更に好ましくは７０～２５０重量部、更に好ましくは１００～２００重量部である。
From the viewpoint of body absorbability of component B in the present invention 1,
The blending ratio of components A and B is, with respect to 100 parts by weight of component A,
Component B is preferably 30 to 500 parts by weight, more preferably 50 to 400 parts by weight, still more preferably 60 to 300 parts by weight, still more preferably 70 to 250 parts by weight, still more preferably 100 to 200 parts by weight.
成分Ａ及びＢの配合比は、本発明１の液状性の観点から、より好ましくは、
成分Ａ１００重量部に対して、
成分Ｂが、２０～３００重量部、好ましくは２５～２５０重量部、より好ましくは３０～２００重量部、更に好ましくは３５～１５０重量部、更に好ましくは４０～１３０重量部、更に好ましくは５０～１２０重量部、である。
From the viewpoint of the liquidity of the present invention 1, the blending ratio of components A and B is more preferably
Per 100 parts by weight of component A,
Component B is 20 to 300 parts by weight, preferably 25 to 250 parts by weight, more preferably 30 to 200 parts by weight, still more preferably 35 to 150 parts by weight, still more preferably 40 to 130 parts by weight, still more preferably 50 to 120 parts by weight.
本発明１における成分Ｂの体内吸収性の観点から、
成分Ｂ１と成分Ｂ２の配合比は、
成分Ｂ１と成分Ｂ２の重量比（Ｂ１／Ｂ２）は、
好ましくは１００／０～１０／９０、９０／１０～３０／７０、より好ましくは８５／１５～５０／５０、更に好ましくは８０／２０～７０／３０である
From the viewpoint of body absorbability of component B in the present invention 1,
The blending ratio of component B1 and component B2 is
The weight ratio (B1/B2) of component B1 and component B2 is
Preferably 100/0 to 10/90, 90/10 to 30/70, more preferably 85/15 to 50/50, still more preferably 80/20 to 70/30
本発明１におけるＲＮＡによる脳の活性維持の観点から、さらに、本発明１の液状性の観点からも、成分Ａ及び成分Ｃの配合量は、
成分Ａ１００重量部に対して、成分Ｃが、
好ましくは５０～１０００重量部、より好ましくは１００～８００重量部、更に好ましくは１５０～６００重量部、更に好ましくは１８０～５００重量部、更に好ましくは２００～４００重量部である。
From the viewpoint of maintaining brain activity by RNA in Invention 1, and also from the viewpoint of liquidity in Invention 1, the amount of component A and component C to be blended is
Per 100 parts by weight of component A, component C is
It is preferably 50 to 1000 parts by weight, more preferably 100 to 800 parts by weight, still more preferably 150 to 600 parts by weight, still more preferably 180 to 500 parts by weight, still more preferably 200 to 400 parts by weight.
本発明１の液状性の観点から、成分Ａ１００重量部に対して、成分Ｃが、
好ましくは２００～１０００重量部、より好ましくは２５０～９００重量部、更に好ましくは３００～８００重量部、更に好ましくは４００～７００重量部、更に好ましくは５００～６００重量部である。
From the viewpoint of the liquidity of the present invention 1, component C is
It is preferably 200 to 1000 parts by weight, more preferably 250 to 900 parts by weight, still more preferably 300 to 800 parts by weight, still more preferably 400 to 700 parts by weight, still more preferably 500 to 600 parts by weight.
本発明１の液状性の観点から、より好ましくは、成分Ａ１００重量部に対して、成分Ｃが、好ましくは２００～１０００重量部、より好ましくは２５０～９００重量部、更に好ましくは３００～８００重量部、更に好ましくは４００～７００重量部、更に好ましくは５００～６００重量部である。 From the viewpoint of the liquidity of the present invention 1, more preferably component C is preferably 200 to 1000 parts by weight, more preferably 250 to 900 parts by weight, still more preferably 300 to 800 parts by weight with respect to 100 parts by weight of component A. parts, more preferably 400 to 700 parts by weight, more preferably 500 to 600 parts by weight.
本発明１における成分Ｃの製造簡易性の観点から、
成分Ｃ１と成分Ｃ２の配合比は、
成分Ｃ１と成分Ｃ２の重量比（Ｃ１／Ｃ２）は、好ましくは１００／０～０／１００、より好ましくは１００／０～５０／５０、更に好ましくは１００／０～８０／２０、更に好ましくは１００／０～９０／１０である。
From the viewpoint of ease of production of component C in the present invention 1,
The blending ratio of component C1 and component C2 is
The weight ratio (C1/C2) of component C1 and component C2 is preferably 100/0 to 0/100, more preferably 100/0 to 50/50, still more preferably 100/0 to 80/20, still more preferably 100/0 to 90/10.
本発明１の液状性及び栄養バランスの観点から、
本発明１中、成分Ａ～Ｃの合計の配合量は、好ましくは２～５０重量％、より好ましくは３～３０重量％、更に好ましくは４～１５重量％、更に好ましくは５～１２重量％、更に好ましくは６～１０重量％である。
From the viewpoint of liquidity and nutritional balance of the present invention 1,
In the present invention 1, the total amount of components A to C is preferably 2 to 50% by weight, more preferably 3 to 30% by weight, even more preferably 4 to 15% by weight, still more preferably 5 to 12% by weight. , more preferably 6 to 10% by weight.
本発明１の液状性及び栄養バランスの観点から、
本発明１中、成分Ａ～Ｃの合計の配合量は、
より好ましくは２～５０重量％、更に好ましくは３～３０重量％、更に好ましくは４～１５重量％、更に好ましくは５～１２重量％、更に好ましくは６～１０重量％である。
From the viewpoint of liquidity and nutritional balance of the present invention 1,
In the present invention 1, the total blending amount of components A to C is
More preferably 2 to 50% by weight, still more preferably 3 to 30% by weight, still more preferably 4 to 15% by weight, still more preferably 5 to 12% by weight, still more preferably 6 to 10% by weight.
本発明１のｐＨは、本発明１の液状性、栄養バランスの観点から、好ましくは３．０～７．０、より好ましくは３.３～６．５、更に好ましくは３．５～６、更に好ましくは３．８～５．５、更に好ましくは４．０～５．２、更に好ましくは４．０～５．０、更に好ましくは４．２～４．５である。 The pH of Invention 1 is preferably 3.0 to 7.0, more preferably 3.3 to 6.5, still more preferably 3.5 to 6, from the viewpoint of the liquidity and nutritional balance of Invention 1. More preferably 3.8 to 5.5, more preferably 4.0 to 5.2, still more preferably 4.0 to 5.0, still more preferably 4.2 to 4.5.
本発明１のｐＨは、本発明１の液状性、栄養バランスの観点から、より好ましくは４．０以上、より好ましくは４.０～７．０、更に好ましくは４．０～６．０、更に好ましくは４．０～５．５、更に好ましくは４．０～５．２、更に好ましくは４．２～５．０である。 The pH of Invention 1 is more preferably 4.0 or higher, more preferably 4.0 to 7.0, still more preferably 4.0 to 6.0, from the viewpoint of the liquidity and nutritional balance of Invention 1. More preferably 4.0 to 5.5, still more preferably 4.0 to 5.2, still more preferably 4.2 to 5.0.
〔本発明２〕
本発明２は、成分Ａ，成分Ｂ、成分Ｃ及び成分Ｄを混合する工程を含む液状の飲料組成物である本発明１の製造方法である。
[Invention 2]
Invention 2 is the production method of Invention 1, which is a liquid beverage composition comprising a step of mixing component A, component B, component C and component D.
成分Ａ～Ｃを含む原料は、それぞれ、水溶液、懸濁液、ゼリー状又は乾燥粉末等の形態であってよく、成分Ａ～Ｃからなる群から選ばれる２種以上の成分が予め混合されていてもよい。 The raw materials containing components A to C may each be in the form of an aqueous solution, suspension, jelly, dry powder, or the like, and two or more components selected from the group consisting of components A to C are mixed in advance. may
成分Ａ～Ｃ原料及び他の添加剤原料に水分が含まれている場合、これらの原料に含まれる水分は成分Ｄを構成する。 If the ingredients A-C ingredients and other additive ingredients contain moisture, the moisture contained in these ingredients constitutes ingredient D.
本発明２は、以下の工程を経ることが好ましい。 Invention 2 preferably undergoes the following steps.
《工程Ａ》
工程Ａでは、成分Ａ～Ｃ原料を成分Ｄ（水分）に溶解して、成分Ａ～Ｃ原料の水溶液を得る。
さらに添加剤原料を添加しない場合は、成分Ａ～Ｃ原料の水溶液は本発明１である。
<<Process A>>
In step A, raw materials for components A to C are dissolved in component D (moisture) to obtain an aqueous solution of raw materials for components A to C.
Furthermore, when no additive raw material is added, the aqueous solution of component A to C raw materials is invention 1.
《工程Ｂ》
工程Ｂでは、工程Ａで得た成分Ａ～Ｃ原料の水溶液に、必要に応じて添加剤原料及び成分Ｄ（水分）を添加して、成分Ａ～Ｃ原料及び添加剤原料の水溶液を得る。得られた成分Ａ～Ｃ原料及び添加剤原料の水溶液は本発明１である。
《Process B》
In step B, an additive raw material and component D (moisture) are added to the aqueous solution of component A to C raw materials obtained in step A, if necessary, to obtain an aqueous solution of component A to C raw materials and additive raw materials. The resulting aqueous solutions of component A to C raw materials and additive raw materials are present invention 1.
《工程Ａの態様例１》
工程Ａは、さらに以下の態様の工程であることが好ましく、以下の態様の工程を単独又は組合わせることがより好ましい。
<<Aspect Example 1 of Step A>>
Step A is preferably a step of the following aspects, and more preferably the steps of the following aspects alone or in combination.
（工程Ａ-１）
成分Ａ１００重量部に対して、成分Ｃの配合量を好ましくは３００～８００重量部、更に好ましくは４００～７００重量部、更に好ましくは５００～６００重量部にして、成分Ａ～Ｃ原料を成分Ｄ（水分）に添加して、攪拌して溶解する。
(Step A-1)
The amount of component C is preferably 300 to 800 parts by weight, more preferably 400 to 700 parts by weight, and still more preferably 500 to 600 parts by weight with respect to 100 parts by weight of component A, and the raw materials of components A to C are added to component D Add to (moisture) and stir to dissolve.
製造結果物の液状性の観点から、より好ましくは、成分Ａ１００重量部に対して、成分Ｃの配合量を好ましくは５０～５００重量部、より好ましくは６０～４５０重量部、更に好ましくは７０～４００重量部、更に好ましくは９０～３５０重量部、更に好ましくは１００～３００重量部にして、成分Ａ～Ｃ原料を成分Ｄ（水分）に添加して、攪拌して溶解する。 From the viewpoint of liquidity of the production result, more preferably, the amount of component C is preferably 50 to 500 parts by weight, more preferably 60 to 450 parts by weight, more preferably 70 to 70 parts by weight with respect to 100 parts by weight of component A. 400 parts by weight, more preferably 90 to 350 parts by weight, more preferably 100 to 300 parts by weight, ingredients A to C are added to component D (moisture) and dissolved by stirring.
（工程Ａ-２）
成分Ａ～Ｃ原料をｐＨの高い又は低い順に成分Ｄ（水分）に添加して、攪拌して溶解する。
(Step A-2)
Components A to C raw materials are added to component D (moisture) in descending order of pH and stirred to dissolve.
なお、成分Ａ～Ｃ原料のｐＨは、日本で使用される硬度４０～９０の温度２５℃の水道水１００ｇに、乾燥粉末状の成分Ａ～Ｃ原料をそれぞれ1.0ｇを添加して攪拌溶解したときのそれぞれのｐＨをいう。 The pH of the raw materials for components A to C was determined by adding 1.0 g of dry powdered raw materials for components A to C to 100 g of tap water at a temperature of 25°C and having a hardness of 40 to 90, which is used in Japan, and stirring and dissolving them. It refers to the pH of each time.
（工程Ａ-３）
成分Ａ～Ｃ原料を混合して、成分Ｄ（水分）に添加して、成分Ａ～Ｄの混合液を好ましくは２５℃超６０℃以下、より好ましくは３０～５０℃、更に好ましくは３５～４５℃に加温して攪拌して溶解する。
(Step A-3)
Components A to C raw materials are mixed and added to component D (moisture), and the mixed liquid of components A to D is preferably above 25° C. and 60° C. or less, more preferably 30 to 50° C., still more preferably 35 to 35° C. Heat to 45° C. and stir to dissolve.
製造結果物の液状性の観点から、より好ましくは、成分Ａ～Ｃ原料を混合して、成分Ｄ（水分）に添加して、成分Ａ～Ｄの混合液を好ましくは３０～９５℃、より好ましくは３５～９５℃、更に好ましくは３７～８５℃以下、更に好ましくは４０～７５℃以下、更に好ましくは４０～６５℃、更に好ましくは４０～５５℃で攪拌して溶解する。 From the viewpoint of the liquidity of the production result, it is more preferable to mix the raw materials of components A to C and add them to component D (moisture) so that the mixed liquid of components A to D is preferably 30 to 95 ° C. Dissolve by stirring at a temperature of preferably 35 to 95°C, more preferably 37 to 85°C, more preferably 40 to 75°C, still more preferably 40 to 65°C, still more preferably 40 to 55°C.
予め上記温度に加温した成分Ｄに、成分Ａ～Ｃ原料混合物を添加してもよいし、
常温の成分Ｄに成分Ａ～Ｃ原料混合物を添加して攪拌しながら、成分Ａ～Ｄの混合液の容器を直接又は湯浴等して加温してもよい。
The raw material mixture of components A to C may be added to component D heated in advance to the above temperature,
The raw material mixture of components A to C may be added to component D at room temperature and stirred while the container containing the mixture of components A to D may be heated directly or in a hot water bath.
（工程Ａ-４）
成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を混合して、前記成分Ｄに添加して、成分Ａ～Ｄの混合液を、ｐＨ４．０以上で攪拌して溶解する。
(Step A-4)
Raw materials containing components A, B, and C as main components are mixed, added to component D, and the mixture of components A to D is stirred at pH 4.0 or higher to dissolve.
添加剤中の、クエン酸やビタミンＣのような酸性が比較的強い成分は、成分Ａ～Ｄの混合液のｐＨが４．０以上を維持するように添加速度や添加順序を調整することが好ましい。 For relatively strongly acidic components such as citric acid and vitamin C in the additive, the rate of addition and order of addition can be adjusted so that the pH of the mixture of components A to D is maintained at 4.0 or higher. preferable.
（本発明２の共通事項）
工程Ａ－１及び工程Ａ－２でも、成分Ａ～Ｄの混合液を好ましくは２５℃超６０℃以下、より好ましくは３０～５０℃、更に好ましくは３５～４５℃（製造結果物の液状性の観点からは、好ましくは３０～９５℃、より好ましくは３５～９５℃、更に好ましくは３７～８５℃、更に好ましくは４０～７５℃、更に好ましくは４０～６５℃、更に好ましくは４０～５５℃）に加温して攪拌して溶解させてもよい。
(Matters common to Invention 2)
Also in steps A-1 and A-2, the mixture of components A to D is preferably above 25° C. and 60° C. or less, more preferably 30 to 50° C., still more preferably 35 to 45° C. From the viewpoint of, preferably 30 to 95 ° C., more preferably 35 to 95 ° C., still more preferably 37 to 85 ° C., still more preferably 40 to 75 ° C., still more preferably 40 to 65 ° C., still more preferably 40 to 55 °C) and stirred to dissolve.
工程Ａ及び工程Ａ－１～３では、得られた成分Ａ～Ｃ原料水溶液のｐＨは、本発明１の好適ｐＨの範囲（好ましくは３．０～７．０、より好ましくは３.３～６．５、更に好ましくは３．５～６、更に好ましくは３．８～５．５（製造結果物の液状性の観点からは、より好ましくは４.０～７．０、更に好ましくは４．０～６．０、更に好ましくは４．０～５．５、更に好ましくは４．０～５．２、更に好ましくは４．２～５．０）に制御することが好ましく、必要に応じてｐＨ調整剤を成分Ａ～Ｃ原料と共に成分Ｄ（水分）に添加してよく、工程Ａ－２では成分Ａ～Ｃの後に添加することが好ましい。 In Step A and Steps A-1 to A-3, the pH of the obtained component A to C raw material aqueous solutions is within the preferred pH range of the present invention 1 (preferably 3.0 to 7.0, more preferably 3.3 to 6.5, more preferably 3.5 to 6, more preferably 3.8 to 5.5 (from the viewpoint of the liquidity of the produced product, more preferably 4.0 to 7.0, more preferably 4 .0 to 6.0, more preferably 4.0 to 5.5, more preferably 4.0 to 5.2, more preferably 4.2 to 5.0), and if necessary The pH adjuster may be added to component D (moisture) together with ingredients A to C, and is preferably added after components A to C in step A-2.
工程Ａ－３の段階で、成分Ａ～Ｃ及原料び添加剤原料を予め混合しておいて工程Ａ－３を適用しても成分Ａ～Ｃ及原料び添加剤原料が成分Ｄ（水分）に溶解するようであれば、工程Ａ－３だけで成分Ａ～Ｄ及原料び添加剤原料の水溶液である本発明１を得ることができる。 In the stage of step A-3, even if components A to C and raw materials and additive raw materials are mixed in advance and step A-3 is applied, components A to C and raw materials and additive raw materials become component D (moisture). , it is possible to obtain the present invention 1, which is an aqueous solution of components A to D and raw materials for additives, only in step A-3.
〔実施例〕
（原料）
以下の粉末状原料を使用した。
〔Example〕
(material)
The following powdered raw materials were used.
（１）成分Ａ原料：製品名『水溶性白子核タンパク』（ＤＮＡ含有量は４０重量％）
（２）成分Ｂ１原料：製品名『ＤＮＡ-Ｎａ』（成分Ｂ１は８５重量％）
（３）成分Ｂ２原料：製品名『ＤＮＡ-Ｎａ（Ｆ）』（成分Ｂ２は９０重量％）
（４）成分Ｃ１原料：製品名『ＲＮＡ』（成分Ｃ１は８５重量％）
（５）成分Ｃ２原料：製品名『ＲＮＡ－Ｗ』（成分Ｃ２は８５重量％）
（６）成分Ｄ：水道水
（７）クエン酸：無水、純度99.5％（ヘルシーカンパニー社製）
（８）クエン酸ナトリウム：食品添加物クエン酸ナトリウム（松葉薬品社製）
(1) Component A raw material: product name "water-soluble milt nucleus protein" (DNA content is 40% by weight)
(2) Component B1 raw material: product name "DNA-Na" (85% by weight of component B1)
(3) Component B2 raw material: product name "DNA-Na (F)" (component B2 is 90% by weight)
(4) Component C1 raw material: product name “RNA” (component C1 is 85% by weight)
(5) Component C2 raw material: product name “RNA-W” (component C2 is 85% by weight)
(6) Component D: tap water (7) Citric acid: anhydrous, purity 99.5% (manufactured by Healthy Company)
(8) Sodium citrate: food additive sodium citrate (manufactured by Matsuba Pharmaceutical Co., Ltd.)
以下の実施例及び比較例の混合物を室温（２５℃）下で作成した。 Mixtures of the following examples and comparative examples were prepared at room temperature (25°C).
（実施例１-1～2及び比較例１-1～3）
成分Ａ～Ｄが表１記載の重量部になるように、
成分Ａ～Ｄ原料をそれぞれ表１記載の重量（ｍｇ）の１０倍量を秤量して、
表１の上からの記載順に成分Ａ～Ｃ原料を、
200mlビーカー中に入れた成分Ｄに攪拌棒で攪拌しながら添加した。
(Examples 1-1 to 2 and Comparative Examples 1-1 to 3)
so that components A to D are in the parts by weight listed in Table 1,
Weigh 10 times the weight (mg) shown in Table 1 for each of the components A to D raw materials,
Components A to C raw materials in the order listed from the top of Table 1,
Add to component D in a 200 ml beaker while stirring with a stir bar.
（実施例２-1～5）
成分Ａ～Ｄ、クエン酸及びクエン酸ナトリウムが表３記載の重量部になるように、
成分Ａ～Ｄ原料、クエン酸及びクエン酸ナトリウムをそれぞれ表２記載の重量（ｍｇ）の１０倍量を秤量して、実施例２-4以外は、
表２に記載の添加順で成分Ａ～Ｃ原料、クエン酸及びクエン酸ナトリウムを、
200mlビーカー中に入れた成分Ｄに攪拌棒で攪拌しながら添加した。
(Examples 2-1 to 5)
so that components A to D, citric acid and sodium citrate are in the parts by weight shown in Table 3,
Components A to D raw materials, citric acid and sodium citrate were each weighed 10 times the weight (mg) shown in Table 2, and except for Example 2-4,
Components A to C raw materials, citric acid and sodium citrate in the order of addition described in Table 2,
Add to component D in a 200 ml beaker while stirring with a stir bar.
実施例２-4は、予め混合した成分成分Ａ～Ｃ原料及びクエン酸混合物を、
200mlビーカー中に入れた成分Ｄに攪拌棒で攪拌して混合液とし、
混合液の入った200mlビーカーを湯浴して混合液を４０℃に加温して攪拌混合した。
Examples 2-4 contain premixed ingredients A to C and a citric acid mixture of
Ingredient D placed in a 200 ml beaker was stirred with a stirring rod to form a mixed solution,
A 200 ml beaker containing the mixture was heated to 40° C. in a hot water bath, and the mixture was stirred and mixed.
実施例２-5は、予め混合した成分成分Ａ～Ｃ原料及びクエン酸混合物を、
200mlビーカー中に入れた成分Ｄに攪拌棒で攪拌して混合液とし、
混合液の入った200mlビーカーに加温した成分Ｄ（水分）を加えて混合液を４０℃にして攪拌混合した。
Examples 2-5 contain premixed ingredients A to C and a citric acid mixture of
Ingredient D placed in a 200 ml beaker was stirred with a stirring rod to form a mixed solution,
A heated component D (moisture) was added to a 200 ml beaker containing the mixed solution, and the mixed solution was heated to 40° C. and mixed with stirring.
（製品実施例１-1～2）
実施例１-1～2で得た成分Ａ～Ｄ原料水溶液に、表４に記載した添加剤を、表４記載の重量（ｍｇ）の１０倍量を秤量して、さらに添加して、攪拌溶解して得た成分Ａ～Ｄ及び添加剤水溶液をそれぞれ製品実施例１-1～2とした。
(Product Examples 1-1 to 2)
10 times the weight (mg) shown in Table 4 was weighed and added to the component A to D raw material aqueous solutions obtained in Examples 1-1 and 1-2, and stirred. Components A to D obtained by dissolution and aqueous additive solutions were designated as Product Examples 1-1 and 1-2, respectively.
（製品実施例２-3～5）
実施例２-3～5で得た成分Ａ～Ｄ原料及び添加剤水溶液に、表４に記載した添加剤を、表４記載の重量（ｍｇ）の１０倍量を秤量して、さらに添加して、攪拌溶解して得た成分Ａ～Ｄ原料及び添加剤水溶液をそれぞれ製品実施例３-3～5とした。
(Product examples 2-3 to 5)
Additives shown in Table 4 were weighed 10 times the weight (mg) shown in Table 4 and added to the ingredients A to D obtained in Examples 2-3 to 2-5 and the additive aqueous solution. The components A to D raw materials and additive aqueous solutions obtained by stirring and dissolving were designated as Product Examples 3-3 to 3-5, respectively.
（評価条件）
（１）ｐＨ
（１－１）成分Ｄ以外の各原料のｐＨは、ビーカーに入れた日本で使用される硬度４０～９０の温度２５℃の水道水１００ｇに、乾燥粉末状の各原料それぞれ1.0ｇを添加して攪拌混合したときのｐＨをｐＨ測定器（Apera社製「エコノミータイプＰＨ２０」）で測定した。
(Evaluation conditions)
(1) pH
(1-1) The pH of each raw material other than component D was determined by adding 1.0 g of each dry powdered raw material to 100 g of tap water with a hardness of 40 to 90 and a temperature of 25°C used in Japan in a beaker. The pH at the time of stirring and mixing was measured with a pH measuring device ("Economy type PH20" manufactured by Apera).
（１－２）成分ＤのｐＨは、ビーカーに入れた成分Ｄ１００ｇのｐＨをｐＨ測定器（Apera社製「エコノミータイプＰＨ２０」）で測定した。 (1-2) The pH of Component D was measured by measuring the pH of 100 g of Component D placed in a beaker with a pH meter ("Economy Type PH20" manufactured by Apera).
（１－３）実施例２-1～5のｐＨは、各実施例でビーカー中に得られた水溶液のｐＨを（Apera社製「エコノミータイプＰＨ２０」）で測定した。 (1-3) For the pH of Examples 2-1 to 2-5, the pH of the aqueous solution obtained in the beaker in each Example was measured using ("Economy type PH20" manufactured by Apera).
（２）液体状態
各実施例及び各比較例でビーカー中に得られた混合物の溶解状態を目視観察して、
浮遊物及び／又は沈殿物が認められずに透明である場合（図１参照）を「〇」；
浮遊物及び／又は沈殿物が発生している場合（図２参照）を「×」とした。
(2) Liquid state Visually observe the dissolved state of the mixture obtained in the beaker in each example and each comparative example,
"○" if it is transparent without any floating matter and / or sediment (see Figure 1);
When suspended matter and/or sediments were generated (see FIG. 2), it was marked as "x".
（結果）
以上の原料、配合及び性状を表１～４にまとめた。
(result)
The above raw materials, formulations and properties are summarized in Tables 1-4.
表１から、成分Ａ１００重量部部に対して成分Ｃが５００重量部以下であると、液体状態が不安定である（同じような配合組成で〇になったり×になったりする）ことがわかった。 From Table 1, it can be seen that when component C is 500 parts by weight or less relative to 100 parts by weight of component A, the liquid state is unstable (similar formulation composition results in ◯ or ×). rice field.
表１及び２で液体状態が〇のものは、さらに添加剤を加えても液体状態は〇であった。 In Tables 1 and 2, those with a liquid state of ◯ remained in a liquid state of ◯ even when an additive was added.
表２から、成分Ａ１００重量部部に対して成分Ｃが５００重量部以下であっても、
成分Ａ～Ｃ及びｐＨ調整剤をｐＨの高い順に添加したり（実施例２-1～3）、
成分Ａ～Ｃ及びｐＨ調整剤混合液を加温したり（実施例２-4）すると液体状態は〇になり、
成分Ａ～Ｃ及びｐＨ調整剤をｐＨの高い順に添加して、さらに成分Ａ～Ｃ及びｐＨ調整剤混合液を加温すると実施例２-1～3よりも早く溶解して液体状態が〇の水溶液となった。
From Table 2, even if component C is 500 parts by weight or less with respect to 100 parts by weight of component A,
Add components A to C and pH adjusters in descending order of pH (Examples 2-1 to 3),
When the mixture of components A to C and the pH adjuster is heated (Example 2-4), the liquid state becomes 〇,
When components A to C and the pH adjuster are added in descending order of pH, and the mixture of components A to C and the pH adjuster is heated, it dissolves faster than in Examples 2-1 to 2-3, and the liquid state becomes ◯. An aqueous solution was obtained.
（１）成分Ａ原料：製品名『水溶性白子核タンパク』（ＤＮＡ含有量は４０重量％）
（２）成分Ｂ１原料：製品名『ＤＮＡ-Ｎａ』（成分Ｂ１は８５重量％）
（３）成分Ｂ２原料：製品名『ＤＮＡ-Ｎａ（Ｆ）』（成分Ｂ２は９０重量％）
（４）成分Ｃ１原料：製品名『ＲＮＡ』（成分Ｃ１は８５重量％）
（５）成分Ｃ２原料：製品名『ＲＮＡ－Ｗ』（成分Ｃ２は８５重量％）
(1) Component A raw material: product name "water-soluble milt nuclear protein" ( DNA content is 40% by weight)
(2) Component B1 raw material: product name "DNA-Na" (85% by weight of component B1)
(3) Component B2 raw material: product name "DNA-Na (F)" (component B2 is 90% by weight)
(4) Component C1 raw material: product name “RNA” (component C1 is 85% by weight)
(5) Component C2 raw material: product name “RNA-W” (component C2 is 85% by weight)
（２）液体状態
各実施例及び各比較例でビーカー中に得られた混合物の溶解状態を目視観察して、
浮遊物及び沈殿物が認められずに透明である場合（図１参照）を「〇」；
浮遊物及び／又は沈殿物が発生している場合（図２参照）を「×」とした。
(2) Liquid state Visually observe the dissolved state of the mixture obtained in the beaker in each example and each comparative example,
"○" if it is transparent without any floating matter or sediment (see Figure 1);
When suspended matter and/or sediments were generated (see FIG. 2), it was marked as "x".
Claims (2)
前記成分Ａは水溶性核蛋白であり、
前記成分ＢはＤＮＡの水溶性塩であり、
前記成分ＣはＲＮＡの水溶性塩であり、
前記成分Ｄは水分であり、
前記成分Ａ及び前記成分Ｂの配合比は、
前記成分Ａ１００重量部に対して、前記成分Ｂが２０～３００重量部であり、
前記飲料組成物中、前記成分Ａ、Ｂ及びＣの合計配合量が２～５０重量％である液状の飲料組成物。 A liquid beverage composition containing component A, component B, component C and component D,
The component A is a water-soluble nucleoprotein,
The component B is a water-soluble salt of DNA,
the component C is a water-soluble salt of RNA;
The component D is water,
The blending ratio of the component A and the component B is
The component B is 20 to 300 parts by weight with respect to 100 parts by weight of the component A,
A liquid beverage composition in which the total amount of the components A, B and C is 2 to 50% by weight in the beverage composition.
前記工程が以下の工程１～４から選ばれる１以上の工程含む請求項１記載の液状の飲料組成物の製造方法：
（工程１）
前記成分Ａ１００重量部に対して、
前記成分Ｃの配合量を５０～５００重量部にして、
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を前記成分Ｄに添加して、攪拌して溶解する工程；
（工程２）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を、ｐＨの高い又は低い順に、前記成分Ｄに添加して、攪拌して溶解する工程；
（工程３）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を混合して、前記成分Ｄに添加して、前記成分Ａ～Ｄの混合液を、温度３０～９５℃で溶解する工程；
（工程４）
前記成分Ａ、Ｂ及びＣをそれぞれ主成分として含む原料を混合して、前記成分Ｄに添加して、前記Ａ～Ｄの混合液を、ｐＨ４．０以上で攪拌して溶解する工程。
Dissolving the component A, the component B and the component C in the component D,
The method for producing a liquid beverage composition according to claim 1, wherein the steps include one or more steps selected from the following steps 1 to 4:
(Step 1)
For 100 parts by weight of component A,
The blending amount of the component C is 50 to 500 parts by weight,
A step of adding raw materials containing the components A, B and C as main components to the component D and stirring and dissolving them;
(Step 2)
A step of adding raw materials containing the components A, B and C as main components, respectively, to the component D in order of pH from high to low, and stirring and dissolving them;
(Step 3)
A step of mixing raw materials containing the components A, B and C as main components, adding the mixture to the component D, and dissolving the mixed liquid of the components A to D at a temperature of 30 to 95 ° C.;
(Step 4)
A step of mixing raw materials containing the components A, B and C as main components, adding them to the component D, and stirring and dissolving the mixture of the components A to D at a pH of 4.0 or higher.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2023/004778 WO2023157802A1 (en) | 2021-09-14 | 2023-02-13 | Liquid beverage composition and method for producing same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021149370 | 2021-09-14 | ||
| JP2021149370 | 2021-09-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP7180935B1 JP7180935B1 (en) | 2022-11-30 |
| JP2023042506A true JP2023042506A (en) | 2023-03-27 |
Family
ID=84271380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022531A Active JP7180935B1 (en) | 2021-09-14 | 2022-02-17 | liquid beverage composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7180935B1 (en) |
| WO (1) | WO2023157802A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0851953A (en) * | 1994-08-08 | 1996-02-27 | J One Prod Kk | Manufacture of nucleic acid food, nucleic acid health drink and nucleic acid cosmetic |
| JP2004016142A (en) * | 2002-06-18 | 2004-01-22 | Ls Corporation:Kk | Formulation containing collagen and water soluble decomposed product of nucleoprotein |
| JP2004231565A (en) * | 2003-01-30 | 2004-08-19 | Nissei Bio Kk | Cancer cell growth inhibitor and health food containing the same |
| JP2007117014A (en) * | 2005-10-28 | 2007-05-17 | Nissan Chem Ind Ltd | Nutritive supplement for preventing rheumatoid arthritis |
| WO2013054525A1 (en) * | 2011-10-12 | 2013-04-18 | フォーデイズ株式会社 | Glutathione-containing health drink |
| JP2020022388A (en) * | 2018-08-07 | 2020-02-13 | 株式会社Ｍｌｆ | Method for producing protein-containing acidic beverage |
-
2022
- 2022-02-17 JP JP2022022531A patent/JP7180935B1/en active Active
-
2023
- 2023-02-13 WO PCT/JP2023/004778 patent/WO2023157802A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0851953A (en) * | 1994-08-08 | 1996-02-27 | J One Prod Kk | Manufacture of nucleic acid food, nucleic acid health drink and nucleic acid cosmetic |
| JP2004016142A (en) * | 2002-06-18 | 2004-01-22 | Ls Corporation:Kk | Formulation containing collagen and water soluble decomposed product of nucleoprotein |
| JP2004231565A (en) * | 2003-01-30 | 2004-08-19 | Nissei Bio Kk | Cancer cell growth inhibitor and health food containing the same |
| JP2007117014A (en) * | 2005-10-28 | 2007-05-17 | Nissan Chem Ind Ltd | Nutritive supplement for preventing rheumatoid arthritis |
| WO2013054525A1 (en) * | 2011-10-12 | 2013-04-18 | フォーデイズ株式会社 | Glutathione-containing health drink |
| JP2020022388A (en) * | 2018-08-07 | 2020-02-13 | 株式会社Ｍｌｆ | Method for producing protein-containing acidic beverage |
Non-Patent Citations (2)
| Title |
|---|
| "有限会社バイオケム", ザ・ビジネスモール, 2016年, JPN6021051435, pages 1 - 6, ISSN: 0004828420 * |
| 受託製造事例 TRUSTEE PRODUCT CASE RNA(W), vol. [検索日2022年6月22日], JPN6022029361, 9 March 2019 (2019-03-09), ISSN: 0004828421 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023157802A1 (en) | 2023-08-24 |
| JP7180935B1 (en) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006180812A (en) | Jelly beverage | |
| KR100872457B1 (en) | Process for preparing egg comprising low-chloesterol and high-calcium and the egg thereby | |
| AU2020102282A4 (en) | Immunity-boosting gel candy for children and the method of preparation | |
| JP7180935B1 (en) | liquid beverage composition | |
| JP6041242B2 (en) | Peptides containing tryptophan | |
| KR20100114974A (en) | A functional beverage comprising deep sea water, extract of black garlic, extract of jujubae fructus and organic acid | |
| KR20180065188A (en) | pomegranate drink comprising marine collagen and manufacturing method thereof | |
| JP5142126B2 (en) | Method for producing antioxidant dipeptide | |
| JP5156330B2 (en) | Adipose tissue weight reducing agent | |
| JP2015130840A (en) | Powder food | |
| CN115316670A (en) | Composition for improving skin condition, health-care beverage and preparation method | |
| CN113243477A (en) | Composition for preventing browning of beverage and application thereof | |
| AU2010307691B2 (en) | Fat accumulation suppressor | |
| JP2007045750A (en) | Anti-fatigue agent | |
| RU2358562C1 (en) | Vegetable concentrate for "kazan-bionan-3" functional drink | |
| US10179157B2 (en) | Slim and aqua concentrate having standardized and triple salt stabilized (−)-Hydroxycitric acid from Garcinia cambogia extract for making concentrate and slimming water and their derived product for weight management | |
| CN1158085C (en) | Fe-Ca nutrient combination and its preparation method | |
| JP3915090B2 (en) | Dietary supplement or beverage composition | |
| CN107484829A (en) | A kind of DHA algal oil goat milk piece and preparation method thereof | |
| CN109198339A (en) | A kind of krill fat beverage | |
| EP2258380B1 (en) | Nucleic acid for imparting heat resistance to lactoferrin | |
| JP2010070463A (en) | Nutrition-supplementing beverage | |
| JP7458990B2 (en) | Method for improving the solubility of polymethoxyflavonoids | |
| JP5779796B2 (en) | Brain function improving agent and food and drink for improving brain function | |
| RU2482698C1 (en) | Composition for preparation of alcohol-free jelly beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220217 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220719 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221020 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221101 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7180935 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |